Detection of FOXO1 break-apart status by fluorescence in situ hybridization in atypical alveolar rhabdomyosarcoma
- 40 Downloads
The morphologies of alveolar rhabdomyosarcoma (ARMS) are various. Some cases entirely lack an alveolar pattern and instead display a histological pattern that overlaps with embryonal rhabdomyosarcoma (ERMS). The method of pathological diagnosis of ARMS and ERMS has been updated in the 4th edition of the World Health Organization’s guidelines for classification of skeletal muscle tumors. Under the new guidelines, there is still no molecular test to distinguish between these two subtypes of rhabdomyosarcoma (RMS). In the present study, we applied fluorescent in situ hybridization (FISH) and found that the Forkhead box O1 (FOXO1) gene broke apart, amplified, and displayed an aneuploid signal that was related to the RMS pathological subtype. Aside from the fact that FOXO1 break-apart and its amplification were correlated with atypical ARMS, aneuploidies were usually found in atypical ERMS. In conclusion, our results detail a potential biomarker to improve the accuracy of pathological diagnosis by discriminating between atypical ARMS and atypical ERMS.
Keywordsatypical alveolar rhabdomyosarcoma FOXO1 fluorescence in situ hybridization
Unable to display preview. Download preview PDF.
This work was supported in part by Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX201508), Beijing Health System Top Level Health Technical Personnel Training Plan (20153079), and the Beijing Talents Fund (2015000021469G210).
- Davicioni, E., Finckenstein, F.G., Shahbazian, V., Buckley, J.D., Triche, T.J., and Anderson, M.J. (2006). Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 66, 6936–6946.CrossRefPubMedGoogle Scholar
- Dias, P., Chen, B., Dilday, B., Palmer, H., Hosoi, H., Singh, S., Wu, C., Li, X., Thompson, J., Parham, D., Qualman, S., and Houghton, P. (2000). Strong immunostaining for Myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass. Am J Pathol 156, 399–408.CrossRefPubMedPubMedCentralGoogle Scholar
- Donaldson, S.S., Meza, J., Breneman, J.C., Crist, W.M., Laurie, F., Qualman, S.J., and Wharam, M. (2001). Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma—a report from the IRSG. Int J Radiat Oncol Biol Phys 51, 718–728.CrossRefPubMedGoogle Scholar
- Heerema-McKenney, A., Wijnaendts, L.C.D., Pulliam, J.F., Lopez-Terrada, D., McKenney, J.K., Zhu, S., Montgomery, K., Mitchell, J., Marinelli, R.J., Hart, A.A.M., van de Rijn, M., and Linn, S.C. (2008). Diffuse Myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma. Am J Surgical Pathol 32, 1513–1522.CrossRefGoogle Scholar
- Hostein, I., Andraud-Fregeville, M., Guillou, L., Terrier-Lacombe, M.J., Deminière, C., Ranchère, D., Lussan, C., Longavenne, E., Bui, N.B., Delattre, O., and Coindre, J.M. (2004). Rhabdomyosarcoma: Value of myogenin expression analysis and molecular testing in diagnosing the alveolar subtype. Cancer 101, 2817–2824.CrossRefPubMedGoogle Scholar
- Karunamurthy, A., Hoffner, L., Hu, J., Shaw, P., Ranganathan, S., Yatsenko, S.A., and Surti, U. (2017). Genomic characterization of a metastatic alveolar rhabdomyosarcoma case using FISH studies and CGH+SNP microarray revealing FOXO1-PAX7 rearrangement with MYCN and MDM2 amplification and RB1 region loss. Cytogenet Genome Res 150, 253–261.CrossRefGoogle Scholar
- Mehra, S., de la Roza, G., Tull, J., Shrimpton, A., Valente, A., and Zhang, S. (2008). Detection of FOXO1 (FKHR) gene break-apart by fluorescence in situ hybridization in formalin-fixed, paraffin-embedded alveolar rhabdomyosarcomas and its clinicopathologic correlation. Diagn Mol Pathol 17, 14–20.PubMedGoogle Scholar
- Raney, R.B., Anderson, J.R., Barr, F.G., Donaldson, S.S., Pappo, A.S., Qualman, S.J., Wiener, E.S., Maurer, H.M., and Crist, W.M. (2001). Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for intergroup rhabdomyosarcoma study V. J Pediatr Hematol/Oncol 23, 215–220.CrossRefGoogle Scholar
- Rudzinski, E.R., Anderson, J.R., Hawkins, D.S., Skapek, S.X., Parham, D.M., and Teot, L.A. (2015). The World Health Organization classification of skeletal muscle tumors in pediatric rhabdomyosarcoma: a report from the Children’s Oncology Group. Arch Pathol Lab Med 139, 1281–1287.CrossRefPubMedPubMedCentralGoogle Scholar
- Rudzinski, E.R., Anderson, J.R., Lyden, E.R., Bridge, J.A., Barr, F.G., Gastier-Foster, J.M., Bachmeyer, K., Skapek, S.X., Hawkins, D.S., Teot, L.A., and Parham, D.M. (2014). Myogenin, AP2ß, NOS-1, and HMGA2 are surrogate markers of fusion status in rhabdomyosarcoma. Am J Surgical Pathol 38, 654–659.CrossRefGoogle Scholar
- Rudzinski, E.R., Teot, L.A., Anderson, J.R., Moore, J., Bridge, J.A., Barr, F.G., Gastier-Foster, J.M., Skapek, S.X., Hawkins, D.S., and Parham, D.M. (2013). Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Am J Clinical Pathol 140, 82–90.CrossRefGoogle Scholar
- Sorensen, P.H.B., Lynch, J.C., Qualman, S.J., Tirabosco, R., Lim, J.F., Maurer, H.M., Bridge, J.A., Crist, W.M., Triche, T.J., and Barr, F.G. (2002). PAX3-FKHRandPAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the Children’s Oncology Group. JCO 20, 2672–2679.CrossRefGoogle Scholar
- Stevens, M.C.G., Rey, A., Bouvet, N., Ellershaw, C., Flamant, F., Habrand, J.L., Marsden, H.B., Martelli, H., Sanchez de Toledo, J., Spicer, R.D., Spooner, D., Terrier-Lacombe, M.J., van Unnik, A., and Oberlin, O. (2005). Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology— SIOP Malignant Mesenchymal Tumor 89. JCO 23, 2618–2628.CrossRefGoogle Scholar
- Williamson, D., Missiaglia, E., de Reyniès, A., Pierron, G., Thuille, B., Palenzuela, G., Thway, K., Orbach, D., Laé, M., Fréneaux, P., Pritchard-Jones, K., Oberlin, O., Shipley, J., and Delattre, O. (2010). Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. JCO 28, 2151–2158.CrossRefGoogle Scholar